Role of Artemisia macrocephala as enzymes inhibitor in dementia and nociception! A pharmacological study

• Published in: Pure and applied biology 2016-09, Vol.5 (3), p.538-538
• Main Author: Shah, Ismail
• Format: Article
• Language: English
• Subjects: Alzheimer's disease; Artemisia; Chloroform; Colleges & universities; Dementia; Dementia disorders; Drugs; Enzymes; FDA approval; Hypotheses; Inhibition; Nervous system; Oils & fats; Pain; Rodents
• ISSN: 2304-2478; 2304-2478
• DOI: 10.19045/bspab.2016.50068

This study was conducted for investigating potentials of methanolic extract (Am. CME) and subsequent fractions of Artemisia macrocephala (A. macrocephala) for the inhibition of acetylcholinesterase (AChE), butyrylcholinesterase (BChE) and cyclo-oxygenase (COX-1 and COX-2). Ellman's assay was followed for the investigation of AChE and BChE inhibitory potentials of Am. CME and subsequent fractions of A. macrocephala while cyclo-oxygenase inhibition was investigated using a COX inhibition assay. For AChE inhibitory assay, chloroform (Am.CHF), ethyl acetate (Am.EtOAc) fractions and Am.CME showed 85.76 ± 1.49, 77.50 ± 0.86 and 71.00 ± 1.15 % inhibition of the enzyme respectively at 1000µg/mL concentration. Similarly, for BChE inhibition assay, Am.CHF, Am.EtOAc and Am. CME showed 82.56±0.68, 73.56 ± 1.56 and 68.55±0.81% inhibition of the enzyme respectively at 1000µg/mL concentration. Am.CHF and Am.CME were found to be most active against COX-1 and COX-2. Against COX-1, AmCHF and Am.CME showed 75.23 ± 0.98 and 73.33 ± 0.46% inhibition respectively at 1000µg/mL concentration. Similarly against COX-2, they showed 81.23 ± 1.23 and 79.40 ± 0.46% respectively at 1000µg/mL concentration. It can be concluded from results that Artemisia macrocephala can be used in the treatment of cognitive disorders, along with neurodegenerative ailments, various neuro-pharmacological ailments and certain painful conditions.